Balyasny Asset Management
CLRB icon

Balyasny Asset Management’s Cellectar Biosciences CLRB Stock Holding History

Balyasny Asset Management’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$612K Buy
+220,000
New +$615K ﹤0.01% 2441

Other funds holding CLRB

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return

Balyasny Asset Management's CLRB Position: Q2 2026 in Review

Balyasny Asset Management opened a new position in Cellectar Biosciences (CLRB) in Q2 2026: 220,000 shares worth $612K. The stake represents ﹤0.01% of the portfolio and ranks #2441 among its holdings.

27 funds tracked by Wall St. Rank hold CLRB as of Q2 2026.

  • Balyasny Asset Management held 220,000 shares of Cellectar Biosciences worth $612K as of Q2 2026.
  • Cellectar Biosciences was a new Balyasny Asset Management position in Q2 2026.
  • Cellectar Biosciences made up ﹤0.01% of Balyasny Asset Management's portfolio in Q2 2026, its #2441 holding.
  • 27 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.